• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Acrivon Therapeutics, Inc. - Common Stock (NQ:ACRV)

    1.605 -0.025 (-1.53%)
    Streaming Delayed Price Updated: 9:43 AM EST, Jan 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Acrivon Therapeutics, Inc. - Common Stock

    < Previous 1 2 Next >
    News headline image
    Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
    Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026 
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Announces $130 Million Private Placement Financing
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.